Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

Indian Journal of Dermatology, Venereology and Leprology

Volumn 72, Issue 2, 2006, Pages 173-174

  Sundharam, J ^a,b  

^a Office No 1 ^*

^b Office No 1   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; PREDNISOLONE; RITUXIMAB; STEROID;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LYMPHOMA; CHILL; CYTOTOXICITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; FOLLICULAR LYMPHOMA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MYASTHENIA GRAVIS; PEMPHIGUS; RHEUMATOID ARTHRITIS; SHORT SURVEY; WEGENER GRANULOMATOSIS;

EID: 33646888448     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.25656     Document Type: Short Survey

References (4)

1. Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20+ follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001;137:269-72.
2. Belgi AS, Azeez M, Hoyle C, Williams RE. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol 2006;31:143.
3. Yeh SW, Sami N, Ahmed RA. Treatment of pemphigus vulgaris: Current and emerging options. Am J Clin Dermatol 2005;6:327-42.
4. Arin MJ, Hunzelmann N. Anti-B-cell directed immunotherapy (rituximab) in the treatment of refractory pemphigus: An update. Eur J Dermatol 2005;15:224-30.